As­traZeneca spin­off scores maid­en FDA ap­proval, where it will field Alex­ion com­pe­ti­tion and an im­mi­nent Roche ri­val

About a year af­ter the first-ever FDA ap­proval for pa­tients with neu­romyelitis op­ti­ca spec­trum dis­or­der (NMOSD), the agency has ap­proved a sec­ond ther­a­py for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.